[關(guān)鍵詞]
[摘要]
通過回顧近年來中藥注射劑不良反應(yīng)的相關(guān)文獻(xiàn),主要從藥物自身因素、生產(chǎn)過程中存在的問題、臨床應(yīng)用中的問題等方面分析中藥注射劑臨床不良反應(yīng)事件發(fā)生的原因,提出嚴(yán)格規(guī)范藥品質(zhì)量的監(jiān)控,建立統(tǒng)一的質(zhì)量標(biāo)準(zhǔn);堅(jiān)持辨證用藥,注意藥物的配伍;控制用藥劑型及劑量等方面減少中藥注射劑不良反應(yīng)。
[Key word]
[Abstract]
Through the review on the adverse drug reaction (ADR) relevant reports of Chinese materia medica injection (CMMI) in recent years, we found that the major factors led to the ADR are as follows: the herbs or medicines of themselves,the problems appeared during the production process, and the factors appeared in clinical application. Therefore, we put forward the following suggestions: Establishing a unified standard for the medicine quality and strengthen the monitoring of it; Insisting on the utilization of different medicines according to various syndrome, paying attention to the compatibility of the drugs during the clinical application, and choosing the proper dosage of the drug and dosage form. Various links should be standardized in clinical application of CMMI so as to achieve the aim of clinical treatment.
[中圖分類號(hào)]
[基金項(xiàng)目]
教育部“長江學(xué)者和創(chuàng)新團(tuán)隊(duì)發(fā)展計(jì)劃”資助(IRT0871);中央高校基本科研業(yè)務(wù)費(fèi)專項(xiàng)資金(1112KYQN43)